Vyant Bio (VYNT) Reports In-Line Q2 EPS

Vyant Bio (NASDAQ: VYNT) reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Vyant Bio (VYNT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c